ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

ClinicalTrials.gov ID: NCT03277690

Public ClinicalTrials.gov record NCT03277690. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 8:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Study identification

NCT ID
NCT03277690
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Cortendo AB
Industry
Enrollment
84 participants

Conditions and interventions

Interventions

  • Levoketoconazole Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 25, 2017
Primary completion
Jun 29, 2020
Completion
Aug 30, 2020
Last update posted
Nov 7, 2022

2017 – 2020

United States locations

U.S. sites
13
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
Keck Medical Center University of Southern California HCII, Internal Medicine - Keck Hospital Los Angeles California 90033
Cedars-Sinai Medical Center, Cedars-Sinai Pituitary Center Los Angeles California 90048
UCLA School of Medicine, Medicine/Endocrinology Department Los Angeles California 90095
The Center for Diabetes and Endocrine Care Fort Lauderdale Florida 33312
Emory University, Neurosurgery Atlanta Georgia 30322
Northwestern University, Medicine - Endocrinology Chicago Illinois 60611
Johns Hopkins University, Endocrinology Department Baltimore Maryland 21287
University of Michigan, Comprehensive Endocrine Research, Internal Medicine - MEND Ann Arbor Michigan 48109
Washington University School of Medicine, Endocrinology St Louis Missouri 63110
Columbia University, College of P&S Medicine/Neuro-endocrine Unit New York New York 10032
Memorial Sloan Kettering Cancer Center, Endocrinology New York New York 10065
Oregon Health & Science University, Neurological Surgery Portland Oregon 97239
Allegheny Neuroendocrinology Center, West Penn Allegheny Health System Pittsburgh Pennsylvania 15212

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03277690, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 7, 2022 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03277690 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →